Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADME and Bioavailability of Capivasertib in Healthy Men
NCT05419401Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Apr 2022
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of capivasertib in breast cancer and prostate cancer (PCa) (2 cohorts), sponsored by AstraZeneca. Primary endpoints: Absolute Bioavailability, Time to Maximum Plasma Concentration and 4 more. Started Apr 2022; status: completed.
02
Drugs
capivasertib
03
Conditions
breast cancerprostate cancer (PCa)
Beyond the preview
Go deeper on NCT05419401.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05419401.